Literature DB >> 15486743

Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q.

Leopoldo Sarli1, Lorena Bottarelli, Giovanni Bader, Domenico Iusco, Silvia Pizzi, Renato Costi, Tiziana D'Adda, Marco Bertolani, Luigi Roncoroni, Cesare Bordi.   

Abstract

PURPOSE: Microsatellite instability and loss of heterozygosity of chromosomes 18q, 8p, and 4p are genetic alterations commonly found in colorectal cancer. We investigated whether these genetic markers allow for the stratification of patients with Stage II to III colorectal cancer into groups with different recurrence risks, and with different prognoses.
METHODS: Tumors of 113 patients were evaluated for loss of heterozygosity of chromosomes 18q, 8p, and 4p and for microsatellite instability by use of six microsatellite markers. Genetic alterations involving each of these genetic markers were examined for association with disease recurrences and survival.
RESULTS: Loss of heterozygosity of chromosomes 18q, informative in 96 percent of cases, in Stage III tumors was associated with higher risk of overall recurrence ( P< 0.001), local recurrence ( P< 0.001), distant metastases ( P< 0.001), decreased overall survival ( P= 0.002), and disease-free survival ( P< 0.001). The recurrence rates and survival rates among patients with Stage II colorectal cancer were independent of loss of heterozygosity of chromosome 18q. Stage III and loss of heterozygosity of chromosome 8p also were associated with a higher risk of recurrences when these factors were considered individually. In multivariate analysis, only loss of heterozygosity of chromosome 18q was independently associated with risk of recurrences ( P < 0.001) and with disease-free survival ( P= 0.001). No correlation was observed between microsatellite instability and recurrence rates. However, microsatellite instability was associated with improved overall survival ( P= 0.04) and with a longer disease-free interval ( P= 0.002). Only in five cases (16.7 percent) was it possible to perform resection of recurrences; two of these patients had microsatellite instability tumor. In no cases was it possible to resect recurrence of tumors with loss of heterozygosity of chromosome 18q.
CONCLUSIONS: Loss of heterozygosity of chromosome 18q is an informative genetic marker, which in resected Stage III colorectal cancer can be used to predict recurrences and survival. Microsatellite instability identified cases that, even in the case of recurrence, have a more favorable prognosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15486743     DOI: 10.1007/s10350-004-0628-6

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  17 in total

Review 1.  Progress in the development of prognostic and predictive markers for gastrointestinal malignancies.

Authors:  Crystal S Denlinger; Steven J Cohen
Journal:  Curr Treat Options Oncol       Date:  2007-10

Review 2.  Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.

Authors:  Gustaw Lech; Robert Słotwiński; Maciej Słodkowski; Ireneusz Wojciech Krasnodębski
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

Review 3.  Gene dysregulations driven by somatic copy number aberrations-biological and clinical implications in colon tumors: a paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  Manny D Bacolod; Francis Barany
Journal:  J Mol Diagn       Date:  2010-08-13       Impact factor: 5.568

4.  Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis.

Authors:  Cinzia Azzoni; Lorena Bottarelli; Nicoletta Campanini; Gabriella Di Cola; Giovanni Bader; Antonio Mazzeo; Carlo Salvemini; Silvia Morari; Davide Di Mauro; Enrico Donadei; Luigi Roncoroni; Cesare Bordi; Leopoldo Sarli
Journal:  Int J Colorectal Dis       Date:  2006-09-21       Impact factor: 2.571

5.  Sporadic colorectal carcinomas with low-level microsatellite instability: a distinct subgroup with specific clinicopathological and molecular features.

Authors:  Cinzia Azzoni; Lorena Bottarelli; Stefano Cecchini; Enrico Maria Silini; Cesare Bordi; Leopoldo Sarli
Journal:  Int J Colorectal Dis       Date:  2011-02-19       Impact factor: 2.571

Review 6.  Recent approaches to identifying biomarkers for high-risk stage II colon cancer.

Authors:  Takashi Akiyoshi; Takashi Kobunai; Toshiaki Watanabe
Journal:  Surg Today       Date:  2012-09-09       Impact factor: 2.549

7.  Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers.

Authors:  Shuji Ogino; Katsuhiko Nosho; Natsumi Irahara; Kaori Shima; Yoshifumi Baba; Gregory J Kirkner; Jeffrey A Meyerhardt; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

Review 8.  Profiling Colorectal Cancer in the Landscape Personalized Testing-Advantages of Liquid Biopsy.

Authors:  Donatella Verbanac; Andrea Čeri; Iva Hlapčić; Mehdi Shakibaei; Aranka Brockmueller; Božo Krušlin; Neven Ljubičić; Neven Baršić; Dijana Detel; Lara Batičić; Lada Rumora; Anita Somborac-Bačura; Mario Štefanović; Ivana Ćelap; Alma Demirović; Roberta Petlevski; József Petrik; Marija Grdić Rajković; Andrea Hulina-Tomašković; Ivana Rako; Luciano Saso; Karmela Barišić
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

9.  Chromosome 18q deletion and Smad4 protein inactivation correlate with liver metastasis: A study matched for T- and N- classification.

Authors:  T Tanaka; T Watanabe; Y Kazama; J Tanaka; T Kanazawa; S Kazama; H Nagawa
Journal:  Br J Cancer       Date:  2006-11-07       Impact factor: 7.640

10.  PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.

Authors:  M Frattini; P Saletti; E Romagnani; V Martin; F Molinari; M Ghisletta; A Camponovo; L L Etienne; F Cavalli; L Mazzucchelli
Journal:  Br J Cancer       Date:  2007-10-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.